N/A N=60 Evaluation of Triathlon - a New Total Knee Prosthesis System - Triathlon vs. Duracon
Arthroplasty, Replacement, Knee
Primary: Roentgen Stereophotogrammetric Analysis (RSA) — 0.65; 0.81 mm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=76 Proteiomic Fingerprints of Gastric Juice
Gastric Cancer
Primary: Number of Participants With Accurate Diagnosis for Gastric Cancer — 27; 44 participants
Phase 2 N=87 Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia
Hodgkin's Disease · Lymphoma, Non-Hodgkin
Primary: Maximum Tolerated Dose (MTD) of 90Y-HAT — 15 mci
N/A N=201 Health Literacy Intervention for Informed Consent of Cancer Patients Considering Clinical Trial Participation
Cancer
Primary: Knowledge About Cancer Clinical Trials — 73.4; 61.6 percentage questions answered correctly
Phase 3 N=376 Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
Hypertension
Primary: Change From Baseline in 24-hour Mean Ambulatory Systolic Blood Pressure (maSBP) — -4.26; -1.04 mmHg — p=<0.001
Phase 1 N=19 RENABLATE-II Feasibility Study of Catheter Based Renal Denervation to Treat Resistant Hypertension - 157
Hypertension, Renal
Primary: Incidence of Major Adverse Events That Occurred Within 30 Days Post-procedure. — 0.0 percentage of participants
Phase 2 N=134 Bacterial Genomic Sequencing in Overactive Bladder
Overactive Bladder
Primary: Bacterial Genomic Sequencing — 25; 11; 3; 6 participants
Phase 2 N=97 Safety Trial of Single Versus Multiple Dose Thymoglobulin Induction in Kidney Transplantation
End-Stage Renal Disease · Kidney Failure
Primary: Composite Endpoint of 5 Components: Fever, Hypoxia, Hypotension, Cardiac Events, and Delayed Graft Function — 13; 12 participants — p=0.64
Phase 3 N=437 Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone
Opioid-Induced Bowel Dysfunction
Primary: Change From Baseline in Mean Weekly Spontaneous Bowel Movement (SBM) Frequency in Subjects Without Dose Reduction Prior to Week 8 — 2.4; 2.6 Spontaneous Bowel…
N/A N=200 A Prospective, Multi-Center Study of the Bard® Denali™ Retrievable Inferior Vena Cava Filter System
Pulmonary Embolism
Primary: Technical Success of Placement — 99.5 percentage of participants
N/A N=326 A Prospective, Randomized Multicenter Study to Evaluate the Safety and Efficacy of the ReShape Duo™ Intragastric Balloon System in Obese Subjects
Obesity
Primary: Comparison of Treatment % Excess Weight Loss (EWL) With Control %EWL at Week 24 — 25.1; 11.3 percentage of EWL — p=0.0041
Phase 4 N=62 Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
Pervasive Development Disorders
Primary: Aberrant Behavior Checklist Hyperactivity Subscale — 19.3; 29.7 units on a scale
Phase 2 N=36 Efficacy and Safety of Dexmedetomidine During Non-Invasive Positive Pressure Ventilation
Acute Respiratory Failure
Primary: Tolerability of NIV as Assessed by an NIV Tolerance Score — 99; 67 percentage of time spent tolerant to NIV — p=0.54
N/A N=77 Internet-based Self-help Treatment for Panic Disorder: Two Ways of Complementary Psychological Support
Panic Disorder
Primary: Change From Baseline Score in the Panic Disorder Severity Scale at 8 Weeks and 6 Months. — 15.29; 15.75; 13.08; 10.42 units on a scale (range= 0-28) — p=0.05
Phase 2 N=20 Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome
Alagille Syndrome
Primary: Change From Baseline to Week 13 (End of Treatment) in Fasting Serum Bile Acid Level — -82.864; -49.388; -66.126; -42.157 umol/L — p=0.5740